fda warning letters glp-1 compounders september 2025 warns Ozempic and Mounjaro counterfeit FDA Issues Warning Letters to
Description
Medical literature and post-marketing data have raised concerns about gastrointestinal complications, particularly when these drugs are used long term
38719), which would, if finalized, affect 503B bulk compounding of semaglutide and tirzepatide specifically - though the proposal itself isn't proof of which framework Zevay's named pharmacies actually use
supplementary table R)
& Poole, C
